SEC Form 4 · accession 0001181431-15-000623
ARROWHEAD PHARMACEUTICALS, INC. · ARWR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David L. Lewis
Officer — Chief Scientific Officer
Period of report
Jan 5, 2015
Accepted (ET)
Jan 7, 2015 · 5:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000879407
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 5, 2015 | M | 15,000 | $2.01 | A | 15,000 | D | |
| Common StockF1 | Jan 5, 2015 | S | 15,000 | $8.0069 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.01 | Jan 5, 2015 | M | 15,000 | D | Jun 1, 2013 | May 6, 2023 | Common Stock | 15,000 | 287,500 | D |
Explanation of responses
- F1Represents the weighted average price at which shares were sold within a range between $8.00 and $8.03. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F2Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F3Represents first vesting date. Option vests over four years from date of grant.